DK0490649T3 - En fysisk form af N- 4- 5-(cyklopentyloxycarbonylamino)-1-methylindol-3-ylmethyl -3-methoxybenzoyl -2-methylbenzensulfonamid, fremgangsmåde til fremstilling deraf og farmaceutiske præparater indeholdende den - Google Patents

En fysisk form af N- 4- 5-(cyklopentyloxycarbonylamino)-1-methylindol-3-ylmethyl -3-methoxybenzoyl -2-methylbenzensulfonamid, fremgangsmåde til fremstilling deraf og farmaceutiske præparater indeholdende den

Info

Publication number
DK0490649T3
DK0490649T3 DK91311505.1T DK91311505T DK0490649T3 DK 0490649 T3 DK0490649 T3 DK 0490649T3 DK 91311505 T DK91311505 T DK 91311505T DK 0490649 T3 DK0490649 T3 DK 0490649T3
Authority
DK
Denmark
Prior art keywords
cyclopentyloxycarbonylamino
methylindol
methylbenzenesulfonamide
methoxybenzoyl
ylmethyl
Prior art date
Application number
DK91311505.1T
Other languages
Danish (da)
English (en)
Inventor
Martin Paul Edwards
John David Sherwood
Original Assignee
Zeneca Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zeneca Ltd filed Critical Zeneca Ltd
Application granted granted Critical
Publication of DK0490649T3 publication Critical patent/DK0490649T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D209/24—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with an alkyl or cycloalkyl radical attached to the ring nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DK91311505.1T 1990-12-12 1991-12-11 En fysisk form af N- 4- 5-(cyklopentyloxycarbonylamino)-1-methylindol-3-ylmethyl -3-methoxybenzoyl -2-methylbenzensulfonamid, fremgangsmåde til fremstilling deraf og farmaceutiske præparater indeholdende den DK0490649T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB909027018A GB9027018D0 (en) 1990-12-12 1990-12-12 Heterocyclic compounds

Publications (1)

Publication Number Publication Date
DK0490649T3 true DK0490649T3 (da) 1997-04-21

Family

ID=10686919

Family Applications (1)

Application Number Title Priority Date Filing Date
DK91311505.1T DK0490649T3 (da) 1990-12-12 1991-12-11 En fysisk form af N- 4- 5-(cyklopentyloxycarbonylamino)-1-methylindol-3-ylmethyl -3-methoxybenzoyl -2-methylbenzensulfonamid, fremgangsmåde til fremstilling deraf og farmaceutiske præparater indeholdende den

Country Status (28)

Country Link
US (1) US5294636A (enExample)
EP (1) EP0490649B1 (enExample)
JP (1) JP2650807B2 (enExample)
KR (1) KR100194479B1 (enExample)
CN (2) CN1032469C (enExample)
AP (1) AP286A (enExample)
AT (1) ATE145199T1 (enExample)
AU (1) AU656344B2 (enExample)
CA (1) CA2056067C (enExample)
CZ (1) CZ288151B6 (enExample)
DE (1) DE69123123T2 (enExample)
DK (1) DK0490649T3 (enExample)
ES (1) ES2094797T3 (enExample)
FI (1) FI101296B1 (enExample)
GB (2) GB9027018D0 (enExample)
GR (1) GR3021605T3 (enExample)
HK (1) HK81497A (enExample)
HU (2) HU213109B (enExample)
IE (1) IE914316A1 (enExample)
IL (1) IL100090A (enExample)
MX (1) MX9102475A (enExample)
MY (1) MY108629A (enExample)
NZ (1) NZ240940A (enExample)
PH (1) PH30041A (enExample)
RU (1) RU2107682C1 (enExample)
SK (1) SK279018B6 (enExample)
TW (1) TW222264B (enExample)
ZA (1) ZA919772B (enExample)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0455596T3 (da) * 1990-05-04 1994-11-28 Ciba Geigy Ag Substituerede indoler
IL100091A (en) * 1990-12-12 1998-08-16 Zeneca Ltd Pharmaceutical compositions containing a physical form of n-[4-[5-(cyclopentyloxycarbonyl)amino-1-methyl indol-3-yl-methyl]-2-methylbenzenesulpho-namide and process for their preparation
GB9119001D0 (en) * 1991-09-05 1991-10-23 Ici Plc Pharmaceutical agents
GR1001368B (el) * 1992-10-08 1993-10-29 Ici Plc Φαρμακευτικοί φορείς.
DE4235133A1 (de) * 1992-10-19 1994-04-21 Bayer Ag Kristallines (R)-(-)-2-Cycloheptyl-N-methylsulfonyl-[4-(2-chinolinyl-methoxy)-phenyl]-acetamid
JP3732508B2 (ja) * 1993-10-01 2006-01-05 アストラ・アクチエボラーグ 粉末状薬剤の製造方法
IS1736B (is) 1993-10-01 1999-12-30 Astra Ab Aðferð og tæki sem stuðla að aukinni samloðun agna
GB9723985D0 (en) * 1997-11-14 1998-01-14 Zeneca Ltd Pharmaceutical compositions
GB9726735D0 (en) * 1997-12-18 1998-02-18 Zeneca Ltd Pharmaceutical compositions
GB9900339D0 (en) * 1999-01-09 1999-02-24 Zeneca Ltd Chemical compounds
GB0003305D0 (en) * 2000-02-15 2000-04-05 Zeneca Ltd Pyrimidine derivatives
IL139243A0 (en) * 2000-10-24 2001-11-25 Internat Specialty Products Is Ethanolate of zafirlukast, process for manufacture and pharmaceutical compositions thereof
TWI353979B (en) * 2002-04-10 2011-12-11 Nippon Zoki Pharmaceutical Co Novel crystal form of 5-hydroxy-1-methylhydantoin
US20090317476A1 (en) * 2003-07-31 2009-12-24 Robinson Cynthia B Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a leukotriene receptor antagonist for treatment of asthma or chronic obstructive pulmonary disease
US20050026882A1 (en) * 2003-07-31 2005-02-03 Robinson Cynthia B. Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a leukotriene receptor antagonist for treatment of asthma or chronic obstructive pulmonary disease
US20050113410A1 (en) * 2003-11-03 2005-05-26 Mark Tawa Pharmaceutical salts of zafirlukast
JP2008531721A (ja) * 2005-03-03 2008-08-14 エラン・ファルマ・インターナショナル・リミテッド 複素環式アミド誘導体のナノ粒子状組成物
US20070197467A1 (en) * 2006-02-06 2007-08-23 Srinivasulu Rangineni Zafirlukast compositions
US20090012146A1 (en) * 2007-07-02 2009-01-08 Giridhar Reddy Buggana Solubility-enhanced pharmaceutical compositions comprising zafirlukast
US20090191183A1 (en) * 2007-07-30 2009-07-30 Auspex Pharmaceuticals, Inc. Substituted indoles
TWI469965B (zh) * 2008-12-22 2015-01-21 Ono Pharmaceutical Co 乙炔基吲哚化合物
WO2014012954A1 (en) 2012-07-18 2014-01-23 Takeda Gmbh Treatment of partly controlled or uncontrolled severe asthma
CN103396353B (zh) * 2013-08-23 2015-05-20 海南通用三洋药业有限公司 一种扎鲁司特无定型态及其制备方法
WO2015110394A1 (en) 2014-01-22 2015-07-30 Takeda Gmbh Treatment of partly controlled or uncontrolled severe asthma with a pde4 inhibitor (and in combination with a leukotriene modifier)
PT109030B (pt) * 2015-12-15 2019-09-25 Hovione Farmaciência, S.A. Preparação de partículas inaláveis de zafirlucaste
CA3052071A1 (en) 2017-01-30 2018-08-02 Western New England University Thiol isomerases inhibitors and use thereof
JP2024521736A (ja) 2021-05-19 2024-06-04 クエルシス ファーマ エージー 筋萎縮性側索硬化症の治療に使用するためのケルセチン含有組成物
US20250275936A1 (en) 2022-05-06 2025-09-04 Quercis Pharma AG Method for treating cancers and neurological diseases using quercetin-containing compositions

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4161516A (en) * 1975-07-25 1979-07-17 Fisons Limited Composition for treating airway disease
GB8607294D0 (en) * 1985-04-17 1986-04-30 Ici America Inc Heterocyclic amide derivatives

Also Published As

Publication number Publication date
TW222264B (enExample) 1994-04-11
PH30041A (en) 1996-11-08
GB9126353D0 (en) 1992-02-12
SK279018B6 (sk) 1998-05-06
AU656344B2 (en) 1995-02-02
KR100194479B1 (ko) 1999-06-15
AU8899591A (en) 1992-06-18
NZ240940A (en) 1994-05-26
GR3021605T3 (en) 1997-02-28
CA2056067C (en) 2001-09-04
IL100090A (en) 1996-09-12
US5294636A (en) 1994-03-15
DE69123123D1 (de) 1996-12-19
MY108629A (en) 1996-10-31
ATE145199T1 (de) 1996-11-15
JP2650807B2 (ja) 1997-09-10
HU211125A9 (en) 1995-10-30
DE69123123T2 (de) 1997-03-06
GB9027018D0 (en) 1991-01-30
CN1063100A (zh) 1992-07-29
CN1074411C (zh) 2001-11-07
ES2094797T3 (es) 1997-02-01
KR920012031A (ko) 1992-07-25
HU913863D0 (en) 1992-02-28
IE914316A1 (en) 1992-06-17
FI915825L (fi) 1992-06-13
FI101296B (fi) 1998-05-29
GB2250743B (en) 1995-02-15
CZ288151B6 (en) 2001-05-16
MX9102475A (es) 1992-06-01
CN1032469C (zh) 1996-08-07
CA2056067A1 (en) 1992-06-13
AP9100341A0 (en) 1992-01-31
JPH04266872A (ja) 1992-09-22
FI915825A0 (fi) 1991-12-11
HK81497A (en) 1997-06-27
CN1148491A (zh) 1997-04-30
GB2250743A (en) 1992-06-17
HUT60717A (en) 1992-10-28
RU2107682C1 (ru) 1998-03-27
AP286A (en) 1993-09-26
IL100090A0 (en) 1992-08-18
CS375891A3 (en) 1992-06-17
EP0490649B1 (en) 1996-11-13
EP0490649A1 (en) 1992-06-17
ZA919772B (en) 1992-09-30
HU213109B (en) 1997-02-28
FI101296B1 (fi) 1998-05-29

Similar Documents

Publication Publication Date Title
DK0490649T3 (da) En fysisk form af N- 4- 5-(cyklopentyloxycarbonylamino)-1-methylindol-3-ylmethyl -3-methoxybenzoyl -2-methylbenzensulfonamid, fremgangsmåde til fremstilling deraf og farmaceutiske præparater indeholdende den
DK0477049T3 (da) 3-amido-pyrazolderivater, fremgangsmåde til deres fremstilling og farmaceutiske præparater indeholdende dem
DK0622408T3 (da) Sammensætning og fremgangsmåde til fremstilling af gelatinfrie, bløde kapsler
DK0965591T3 (da) Fremgangsmåde til fremstilling af (S)-3-methyl-1-(2-piperidino-phenyl)-1-butylamin
IL98393A0 (en) Thiophene derivatives,processes for the preparation thereof and pharmaceutical compositions containing the same
FI925661L (fi) Injicerbar farmaceutisk komposition
DK0676438T3 (da) Orienteret film, der er let at spalte, og fremgangsmåde til fremstilling af den
IL99030A0 (en) 1,4-dihydropyridine derivatives,processes for the preparation thereof and pharmaceutical compositions containing the same
FI913775A7 (fi) 17-asemassa substituoidut kortikoidi-17-alkyyliakrbonaatit, menetelmä niiden valmistamiseksi ja niitä sisältävät lääkeaineet
IS3814A (is) Aðferð til framleiðslu á lyfjablöndum
DK4189D0 (da) Oxadiazolforbindelse, farmaceutisk praeparat indeholdende og fremgangsmaade til fremstilling af forbindelsen
KR950700310A (ko) 헤테로트리사이클릭 유도체, 그의 제조방법 및 그를 함유하는 약제학적 조성물(heterotricyclic derivatives, process for their preparation and pharmaceutical compositions containing them)
DK0538303T3 (da) Fremgangsmåde til fremstilling af cycliske sulfater
DK162886C (da) 1,4-dihydropyridin-derivater, fremgangsmaade til fremstilling deraf og farmaceutisk praeparat indeholdende forbindelserne
ZA911804B (en) 1-azabicyclic compounds,processes and pharmaceutical compositions containing them
DK0494966T3 (da) Stærkt brunende flydende røgsammensætning og fremgangsmåde til fremstilling af en stærkt brunende flydende røgsammensætning
DK102990D0 (da) Thieno-triazolodiazepinderivater, fremgangsmaade til fremstilling af saadanne forbindelser og laegemiddel indeholdende disse
IT1290797B1 (it) Composizioni farmaceutiche stabilizzate
DK0565608T3 (da) Fremgangsmåde til fremstilling af urt
DK166088C (da) 2'-deoxy-5-fluoruridinderivater, fremgangsmaade til fremstilling deraf, anticancermidler indeholdende saadanne forbindelser og anvendelse af saadanne forbindelser til fremstilling af anticancermidler
DK635988D0 (da) 1,3-butandiolacetoacetat-derivater og anvendelse af 1,3-butandiolacetoacetat-forbindelser til fremstilling af farmaceutiske praeparater
DE59105224D1 (de) Verfahren zur Herstellung von N-substituierten Pyrrolidonen.
IL99561A0 (en) Heterocyclic compounds,their preparation and pharmaceutical compositions containing them
DK0499157T3 (da) Fremgangsmåde til fremstilling af 1,3-dioxoler
FI922773A7 (fi) Uudet p-substituoidut fenyyli-4-oksibutaaniamiinijohdannaiset, menetel mä niiden valmistamiseksi sekä niitä sisältävät farmaseuttiset koostum ukset